| 29.45 -0.15 (-0.51%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.84  |
1-year : | 40.69 |
| Resists | First : | 29.82 |
Second : | 34.84 |
| Pivot price | 26.6 |
|||
| Supports | First : | 25.05 |
Second : | 22.1 |
| MAs | MA(5) : | 27.88 |
MA(20) : | 25.84 |
| MA(100) : | 24.65 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 93.4 |
D(3) : | 87.9 |
| RSI | RSI(14): 67.4  |
|||
| 52-week | High : | 29.82 | Low : | 14.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLDX ] has closed above the upper band by 2.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 33.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.85 - 30 | 30 - 30.12 |
| Low: | 28.47 - 28.63 | 28.63 - 28.75 |
| Close: | 29.2 - 29.47 | 29.47 - 29.67 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Thu, 04 Dec 2025
Celldex Therapeutics stock hits 52-week high at $29.14 - Investing.com
Thu, 04 Dec 2025
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Wed, 03 Dec 2025
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Thu, 27 Nov 2025
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - news.stocktradersdaily.com
Fri, 21 Nov 2025
How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses - simplywall.st
Wed, 19 Nov 2025
Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 5.624e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 7,400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.5286e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 859.2 % |
| Return on Equity (ttm) | -21.8 % |
| Qtrly Rev. Growth | 2.6e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -28.71 |
| EBITDA (p.s.) | -1.89451e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -179 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.03 |
| Price to Cash Flow | 3.69 |
| Dividend | 0 |
| Forward Dividend | 8.85e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|